MPP Inks Licensing Pacts With Three Generic Drugmakers Over HIV PrEP Drug

The Medicines Patent Pool (MPP) has signed licensing agreements with Aurobindo, Cipla and Viatris to manufacture generic versions of cabotegravir, ViiV Healthcare’s long-acting drug for HIV pre-exposure prophylaxis (PrEP).

MPP is a United Nations initiative aimed at facilitating the development of life-saving medicines for low- and middle-income countries through voluntary licensing and patent pooling.

The new agreement allows the three manufacturers to supply their generic versions of long-acting cabotegravir in 90 countries, contingent upon regulatory approval.

ViiV Healthcare, which is majority-owned by GSK, intends to provide the companies with technical know-how on manufacturing the drug.